Independent information resource

About

Wide Anchor 84 exists to help people approach limited evidence, unresolved questions, and significant safety concerns with steadiness and plain language.

An independent resource on experimental ibogaine research for Parkinson’s.

Hands held together in a quiet, supportive setting

Why we exist

People deserve language that makes room for both hope and uncertainty.

Wide Anchor 84’s working standard

A calmer place to begin

Wide Anchor 84 is built for people with Parkinson’s, care partners, and curious families who want a cautious understanding of experimental ibogaine claims. Our mission is straightforward: Cautious Ginkgo helps people understand the limited evidence, unresolved questions, and significant safety concerns surrounding ibogaine and Parkinson’s disease. It distinguishes early hypotheses from established care.

The main guide to ibogaine Parkinson’s clinical trials provides the topic-focused starting point; this page explains the standards behind the resource. We do not ask readers to trade caution for certainty, or uncertainty for dismissal.

Our editorial approach

Built around what can be checked

We organize information around registries, published literature, and official sources, with attention to what those sources do and do not establish. Clinical trial records are especially useful for describing a study’s stated purpose, eligibility, and status; the ClinicalTrials.gov study registry is one recognized public record for that work.

Scientific restraint We separate findings, hypotheses, and unanswered questions.
Safety awareness We keep significant concerns visible in the conversation.
Plain language We aim for clear wording without oversimplifying uncertainty.
Evidence context We distinguish registered studies from established care.

A wide, peaceful landscape suggesting time for careful consideration

What we cover

A clear route through the material

Our pages are arranged to help readers locate the kind of context they need, from trial landscape and study design to safety questions. The ways this resource organizes evidence and safety context describe that reader-first approach without presenting it as clinical care.

We also point out when a source is not a substitute for a careful clinical conversation. For broad background on how evidence is assessed, the Cochrane explanation of health evidence offers a useful public reference point.

Trial context

How to read study listings, status labels, and stated aims.

Safety context

Why careful framing matters when claims are experimental.

Study questions

What a trial description can clarify and what it cannot.

Reader orientation

Plain-language paths for families sorting through complex material.

Who this is for

For questions that deserve room

Wide Anchor 84 is for people looking for an independent reference, not a sales conversation. We aim to support thoughtful reading for people with Parkinson’s, care partners, and families who may be encountering experimental claims for the first time.

Readers looking for a careful place to orient themselves before drawing conclusions.
Care partners who want language that does not overstate what is known.
Families comparing claims with the limits of publicly available evidence.

How we stay useful

Context first, conclusions later

When sources are limited or incomplete, we say so. When a claim reaches beyond its evidence, we try to make that gap legible. That is the practical meaning of scientific restraint, safety awareness, plain language, evidence context, and independence.

For readers exploring broader conversations, material on ibogaine and opioid addiction belongs to a different context and should not be treated as transferable evidence. The same care applies to discussions of ibogaine claims involving brain injury.

Keeping contexts separate

Different settings, different claims

Location-based treatment marketing can use language that looks similar while describing very different settings. Readers encountering ibogaine treatment information in Colorado or ibogaine treatment discussions in Mexico should keep those contexts separate from the purpose of this independent resource.

We encourage readers to consider the date, source type, and evidentiary limits behind claims. For a public overview of why research participation is governed by ethical principles, the U.S. Belmont Report remains a foundational reference.

Reading with care

Information is not an endorsement

We recognize that people may arrive after following a range of online conversations. Accounts collected through an ibogaine trip report, updates framed as ibogaine news coverage, and discussions of retreat cost questions may raise understandable questions, but none changes this resource’s independent, evidence-first role.